Shaping the Future of Psoriasis through
Advanced Therapeutic Strategies

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2016 Fall Forum. If you participated in
the live session, you are not eligible for continuing education credits from this archive.


This activity is valid from January 15, 2017 to January 31, 2018

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.  To print or save your certificate, you will need to click on the “download” button and either print or save.
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This educational activity is supported by educational grants from
AbbVie, Inc, Celgene Corporation, and Lilly USA, LLC

Description:
Psoriasis is a complex, chronic, immune-mediated inflammatory disease presenting with periodic flare-up of sharply defined red patches, covered by a silvery, flaky surface and affects approximately 7 million people in the US. The disease most commonly appears on the skin of the scalp, elbow, knees, and lumboscaral areas of the body. Many patients are not receiving the appropriate treatment discussed in the current guidelines and standards of care. Psoriasis is a very expensive disease for the American health system and is difficult to manage thus the goal should be patient-centered treatment that reduces cost, disease burden, improves quality-of-life, and addresses the risks of systemic complications and comorbid conditions. There are several treatment options to include topical treatments, from over the counter (OTC) to prescription, phototherapy, laser therapy and traditional systemic medication. Emerging options such as Biologics can be very effective but proper management must be done in order to assure the best safety and efficacy for the patient.

Upon Completion of this activity, participants will be able to:

  • Review the mechanism(s) of action, safety and efficacy of treatment options in treating psoriasis

  • Explore the standard diagnostic criteria for early and moderate to severe patients with psoriasis

  • Analyze the mechanisms of newer biological treatment agents targeting different pathways in patients with moderate to severe psoriasis

  • Describe the benefits and risks of newly available biologic therapies for treatment of psoriasis

  • Review strategies to minimize adverse effects and barriers to care associated with psoriasis treatments
     

Faculty: Gary M. Owens, MD
President
Gary Owens Associates

Disclosure:

Dr. Owens serves as a consultant AbbVie, Biogen, Novartis and Roche. His presentation has been peer reviewed for bias.
 
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

The National Association of Managed Care Physicians designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity and turn in a validation form will receive up to 1 credit in continuing nursing education.

The American Board of Managed Care Nurses has approved this activity for a maximum of 1 contact hour towards CMCN recertification.

This educational activity is supported by educational grants from
AbbVie, Inc, Celgene Corporation, and Lilly USA, LLC

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue